Disc Medicine's Bitopertin Meets All Primary and Secondary Endpoints in Phase 3 EPP Trial
Bitget2026/10/19 11:13- Disc Medicine on Oct. 19, 2026, reported bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial.
- Results in erythropoietic protoporphyria showed increased pain-free time in light, fewer phototoxic reactions and improved quality of life versus placebo.
- Bitopertin was generally well tolerated, with no new safety signals; dizziness was the most common treatment-related adverse event.
- An FDA application resubmission is planned by year-end 2026, with a decision anticipated by mid-2027.
- Topline results were announced; more detailed findings will be presented at a future medical conference.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
AI Bubble Index at 74, CoreWeave (CRWV.US) stock price may fall below $50
CoreWeave's stock price has dropped nearly 70% from its peak to $54.25, with the short interest ratio rising to 15%. As the AI bubble index reaches an extreme value of 74 and the company faces $3 billion in debt pressure, its share price is at risk of falling below the critical support level of $50.
Cramer Beat the S&P At His Hedge Fund But Advises Retail to Join The Index
Trump Calls Off Iran Strike But Will Oil Hold Above $100?
$6 billion acquisition! Medical giant Bausch Health plans to take a controlling stake in Surgery Partners (SGRY.US)
Boston Consulting Group plans to acquire a controlling stake in Surgery Partners for approximately $6 billions, at $20 per share; Bain Capital will retain a 40% stake, and the deal could be announced as early as Monday.
Crypto prices
More
